Oncology · Clinical trials
Medulloblastoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About medulloblastoma — and why its trials are hard
Medulloblastoma is the most common malignant brain tumor of childhood, an embryonal tumor arising in the cerebellum that can spread through the cerebrospinal fluid. Treatment relies on maximal safe surgical resection followed by craniospinal radiotherapy (in children old enough to tolerate it) and multi-agent chemotherapy; there is no medulloblastoma-specific systemically approved targeted drug for most patients. Molecular profiling has redefined the disease into four consensus subgroups—WNT (best prognosis), SHH, Group 3 (often MYC-amplified, worst prognosis), and Group 4—each with distinct biology and outcomes. The SHH subgroup is driven by aberrant Sonic Hedgehog signaling, and Hedgehog pathway inhibitors such as vismodegib showed targeted activity in recurrent SHH medulloblastoma in Pediatric Brain Tumor Consortium studies, though responses were often transient and limited by resistance and, in growing children, bone toxicity. Cure rates for average-risk disease are relatively high but come at the cost of significant neurocognitive, endocrine, and developmental late effects from radiation. Recurrent and Group 3/high-risk disease remain largely incurable, representing a major unmet need for less toxic, subgroup-tailored therapies.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| no medulloblastoma-specific systemic drug approval; standard is surgery, craniospinal radiotherapy, and multi-agent chemotherapy (not applicable) | 0 | Standard of care for newly diagnosed medulloblastoma across risk groups | Cooperative group protocols (e.g., COG ACNS0331, ACNS0332, SIOP-PNET5) | Event-free / progression-free survival and overall survival | Average-risk disease achieves roughly 70-85% 5-year survival with combined-modality therapy; regimens are refinements of standard chemo-radiotherapy rather than novel approved agents (unverified as a single FDA label) |
| vismodegib (Hedgehog pathway inhibitor) (Erivedge) | 2012 | FDA-approved for advanced basal cell carcinoma; used off-label / investigationally in SHH-subgroup medulloblastoma (not FDA-approved for medulloblastoma) | PBTC-025B and PBTC-032 (Pediatric Brain Tumor Consortium) | Objective response / progression-free survival | Targeted activity limited to SHH-subgroup tumors with an intact upstream pathway; responses often transient, no medulloblastoma approval granted |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in medulloblastoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| vismodegib (as durable medulloblastoma therapy) — PBTC-025B / PBTC-032; MEVITEM (vismodegib + temozolomide) | Responses generally short-lived; benefit confined to SHH subgroup and frequently followed by resistance | Downstream pathway mutations (e.g., SUFU, GLI2 amplification) confer resistance; premature growth-plate fusion limits use in children |
| sonidegib (Hedgehog pathway inhibitor) — Phase I/II studies in relapsed medulloblastoma | Activity limited to SHH-pathway-activated tumors with proximal pathway lesions; not approved for medulloblastoma | Same downstream-resistance biology as vismodegib and skeletal toxicity in developing patients |
| intensified/high-dose chemotherapy strategies (various) — Assorted relapsed/high-risk cooperative trials | Failed to reliably cure recurrent or Group 3 high-risk disease | Chemoresistance and inability to safely escalate radiation, especially in young children, limit efficacy |
Choosing the right endpoint
Primary endpoints that matter in medulloblastoma trials
- Progression-free / event-free survival (PFS/EFS) — Core efficacy endpoints in newly diagnosed and relapsed medulloblastoma trials
- Overall survival (OS) — Definitive endpoint, with marked differences across molecular subgroups
- Molecular subgroup (WNT, SHH, Group 3, Group 4) — Central to risk stratification and to interpreting subgroup-specific therapy such as Hedgehog inhibition in SHH tumors
- Neurocognitive and endocrine late effects — Critical long-term outcome measure given the toxicity of craniospinal radiation in developing children
- CSF dissemination / M-stage (Chang staging) — Assesses leptomeningeal spread, a key prognostic and treatment-defining factor
How iNGENū runs medulloblastoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Medulloblastoma clinical trials — FAQs
Are there targeted drugs approved for medulloblastoma?
What are the molecular subgroups and why do they matter?
Why is reducing treatment toxicity a priority?
Ready to discuss your medulloblastoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal